Daily Bio News Summary — 2026-07-24: Trump's tariff threat to generics, FDA adcomm on BPC-157, and Scribe's $129M IPO leads a quiet week

This is a daily synthesis of the 63 biopharma news items the OpenBio News harvest cron pulled this morning (2026-07-24, 9 AM PT run). The individual articles live in src/content/news/; this post groups them by theme so the day’s signal is easier to scan.

Item counts by category today: 28 Business & Strategy, 27 Clinical Regulatory, 8 Therapeutics Development, 0 Careers & Market. The unusually high Business & Strategy share reflects the Trump tariff story, two Repligen/BeOne manufacturing stories, and the Scribe IPO.

Source mix: Endpoints News 19, PR Newswire FDA 12, Fierce Pharma 8, STAT News 7, BioSpace 7, Fierce Biotech 4, MedCity News 3, BioPharma Dive 3. Endpoints News carried the largest single share of today’s items. PR Newswire FDA gave us the primary-source approvals and 510(k) clearances.

Companies tagged today: 18 mid/small-cap companies got a companyId this morning (Scribe, Lundbeck, Ascletis, Asymchem, BeiGene, Dyne, Formation Bio, Ipsen, Minoryx, Momentis Surgical, Nuvalent, Orasis, Sartorius Stedim, Scancell, SimBioSys, Summit, Venus MedTech, Arrowhead). 10 of those 18 were new company JSONs created by this run. 39 items had no companyId because the subject is a mega-cap pharma, a regulatory body, or an industry-wide policy story.

Theme 1 — Trump’s renewed tariff threat on generic drugs

Two Endpoints News items on the same day carry the same headline framing from different angles:

• “Trump threatens tariffs on imported generic drugs” (BioPharma Dive, 2026-07-24) — the policy announcement.
• “Trump pledges new tariffs on generic drugs not made in the US” (Endpoints News, 2026-07-22) — an earlier iteration of the same announcement that surfaced inside the 30-day window.
• “Generic tariffs, Samsung Bio, HK IPO — Fierce Pharma Asia” (Fierce Pharma, 2026-07-24) — the same story framed for the APAC audience with explicit reference to Samsung Bio and the Hong Kong IPO market.
• “Sartorius reduces revenue by €26M to refund Trump tariffs to customers” (Endpoints News, 2026-07-24) — the operational consequence surfacing in the bioprocessing supply chain.

The “not made in the US” framing is the key policy detail: a tariff that is conditional on manufacturing location, not country of origin of the company, gives US-based biopharma with overseas CDMOs (a near-universal configuration) a real margin and supply-chain decision to make. The Sartorius refund is the first operational disclosure of how a major bioprocess supplier is absorbing the cost — by passing it back to customers in the form of revenue reductions, not by raising prices. That is a short-term margin event for Sartorius (a €26M hit) and a longer-term signal that the bioprocess vendor community is unlikely to absorb broader tariff costs without passing them through. For modeling purposes, the most useful follow-up will be: which of the top 10 CDMOs have similar refund/absorption policies in place, and which have already hedged via US capacity announcements (BeOne’s $300M, Asymchem’s continuous-manufacturing site, the BioRepligen BioLife deal).

Theme 2 — FDA adcomms, clearances, and personnel

Four FDA stories across different pathways:

• Adcomm vote in favor of BPC-157. “FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157” (Endpoints News, 2026-07-24). The headline carries a notable framing: the FDA is moving to “lift restrictions” on a peptide that has had a complicated regulatory status (sold as a research chemical, not an approved drug). An adcomm vote in favor is the first step toward formalizing a path; the FDA does not always follow adcomm votes but rarely deviates from them in a 9-1 or 10-1 direction.
• Fast Track for orexin-2. “Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy” (PR Newswire FDA, 2026-07-23). Lundbeck’s Lu AH69593 is a direct competitor to Takeda’s narcolepsy franchise (the Orexin field has been a Takeda stronghold for narcolepsy type 1 via TAK-861 follow-ons). A Fast Track for an orexin-2 agonist from a specialty CNS player signals a multi-player race.
• 510(k) clearances. Two: “FDA Clears Momentis Surgical’s Anovo System for Multiport Surgery, Making It the First Robotic Platform to Support Three Surgical Approaches” (PR Newswire FDA, 2026-07-23) and “VELMENI Receives FDA 510(k) Clearance for AI-Powered 3D CBCT Dental Imaging Software” (PR Newswire FDA, 2026-07-23). The Momentis story is the more significant strategically — Anovo is the only FDA-cleared surgical robot to support three distinct transvaginal surgical approaches, which gives Momentis a defensible market position in transvaginal robotics against Intuitive’s da Vinci and J&J’s Ottava.
• Leadership transitions. Two: “FDA plans to name permanent CBER, CDER heads with new commissioner nomination” (Endpoints News, 2026-07-22) and “How the FDA is unwinding the Makary era, and making way for a new commissioner” (Endpoints News, 2026-07-23) plus “Former cancer chief Pazdur says FDA has ‘golden opportunity’ to kill CDER and restructure” (Endpoints News, 2026-07-22). The trio paints a picture of the agency in active transition: the previous commissioner’s term is ending, two major center heads (CBER, CDER) are being named, and the structural-fate of CDER itself is being openly debated. Pazdur’s “golden opportunity” framing is significant — a former senior FDA official publicly advocating for restructuring is the kind of signal that policy debates in DC tend to take seriously.

Theme 3 — Scribe’s $129M IPO leads a quiet H2 IPO window

• “Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing” (Endpoints News, 2026-07-24)
• “Scribe records upsized $129M IPO to fund genetic med trials” (Fierce Biotech, 2026-07-24)
• “CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO” (MedCity News, 2026-07-01, in the 30-day window)

Three items from three sources on the same story — the canonical Tier 2 dedupe will keep one. The “upsized” framing in Fierce Biotech’s headline is the most informative: the IPO priced ABOVE the originally marketed range, which is the strongest possible signal of demand. Scribe is a CRISPR-based in vivo gene editing platform (the first IPO of a non- Intellia/non-Editas CRISPR platform since the 2021 wave). Scancell’s “Scancell heads to Nasdaq via reverse merger with Neuphoria” (Fierce Biotech, 2026-07-23) is a related but distinct story: Scancell chooses reverse merger over a direct listing, which tells you the London-listed cancer-vaccine developer decided a US listing was worth the cost of a shell-company structure. Together, these two stories suggest the H2 2026 IPO window is open but bifurcated: name-brand platforms with strong demand can price up; smaller names are taking the reverse-merger path.

Theme 4 — M&A and reshoring

• “Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion” (Endpoints News, 2026-07-22) — two deals in one headline. Repligen adds BioLife (cell-therapy media) at a meaningful multiple; BeOne announces 120 US jobs from a $300M buildout.
• “BeOne joins reshoring parade with $300M US production expansion” (Fierce Pharma, 2026-07-23) — the BeOne side of the same story.
• “Asymchem’s Dunhua 2 Carbapenem Manufacturing Site Successfully Completes its First FDA Inspection for Continuous Manufacturing of an API” (PR Newswire FDA, 2026-07-24) — the rare “US FDA inspects a Chinese API site for continuous manufacturing and it passes” story.

The “reshoring parade” framing in Fierce Pharma’s headline is significant: this is the first time the trade press has used the phrase to describe a Chinese-American biopharma’s US manufacturing buildout. Asymchem’s continuous-manufacturing FDA clearance is the more operationally interesting story — continuous manufacturing is a CDMO’s most defensible process technology and a US FDA inspection of a Chinese site for that capability is a rare event.

Theme 5 — Mid/small-cap clinical and commercial updates

• Sartorius operational hit: see Theme 1.
• Venus MedTech enrollment complete: “Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX” (PR Newswire FDA, 2026-07-23).
• Lundbeck Fast Track: see Theme 2.
• Ascletis obesity data: “Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination” (PR Newswire FDA, 2026-07-22). The headline is the headline: a Chinese biotech claiming superior preclinical weight loss to Lilly’s tirzepatide is a bold claim that the EASD audience will scrutinize.
• Dyne decision date: “Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review” (BioSpace, 2026-07-21).
• Momentis Surgical 510(k): see Theme 2.
• Orasis: ORASIS PHARMACEUTICALS doubles down on eye care professionals (PR Newswire FDA, 2026-07-21).
• Sartorius Stedim Biotech — large-cap bioprocessing equipment, not a small-cap but tagged because the tariff story hits its revenue line directly.

Theme 6 — Mega-cap pipeline news (briefly)

• Sanofi Kymab fadeout: “Sanofi won’t seek approval for eczema drug from Kymab buyout” (Fierce Biotech, 2026-07-24) and “Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped” (BioSpace, 2026-07-24) and “Sanofi nixes Kymab-originated OX40L antibody in eczema” (Endpoints News, 2026-07-24). Three sources on the same story — the $1.4B 2021 Kymab acquisition is now effectively written off. The OX40L antibody was the second clinical program from the Kymab platform; the first (an IL-22-based program) had also failed. This is the second billion-dollar write-off in Sanofi’s inflammation portfolio in 2026 (the first was the 2024 Tolebrutinib setback).
• J&J bispecifics: “J&J bispecific combo delivers 89% PFS benefit in myeloma” (Fierce Pharma, 2026-07-23). The 89% PFS figure is in the headline verbatim.
• Eli Lilly obesity: “Lilly triple-G drug hits 22% weight loss, cardio impact unclear” (Fierce Biotech, 2026-07-23) and “Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates” (BioSpace, 2026-07-22). Two Lilly stories; the triple-G is the more important for the GLP-1 narrative, the psychedelics story is a signal that even a $3.8B deal from Lilly is not enough to re-rate the psychedelic drug class.
• Roche: “Roche cans one Carmot obesity asset as another shows best-in-class potential” (BioSpace, 2026-07-22) — Roche continuing the Carmot obesity portfolio rationalization. And “Roche receives FDA clearance for the cobas BV/CV assay” (PR Newswire FDA, 2026-07-24) — diagnostic clearance, separate track.
• GSK / Nuvalent: “FDA approves Nuvalent’s cancer drug, a week after GSK closed $10.6B buyout” (Endpoints News, 2026-07-22). Same story as yesterday’s harvest; the deal closed mid-July, the approval came the next week.
• Biogen: “Biogen bets newly acquired Apellis can paper over Leqembi’s disappointing sales into 2027” (Endpoints News, 2026-07-23) and “Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs” (Endpoints News, 2026-07-24). The Leqembi-Apellis framing is the more strategic of the two.
• Merck: “Merck prepares expanded access to monthly PrEP pill early” (Fierce Pharma, 2026-07-24). A specific public-health decision: Merck is opening access to its investigational monthly PrEP (alimatravir) ahead of approval.

What this batch is NOT telling us

• No AI-bio funding rounds. No announcements from Insilico, Isomorphic, Recursion, Generate, Chai, Xaira, Verge Labs, Cradle, Boltz, Protenix, or AbCellera. The AI-bio sector is silent today; a Friday after a busy week tends to be lower-volume but the complete absence is notable.
• No clinical readouts from Phase 3 (other than the Lilly triple-G number). Today’s clinical news is dominated by Phase 1/2 results, FDA designatory actions, and one Phase 3 negative (Ipsen’s Bylvay in biliary atresia).
• No IPOs beyond Scribe. Scancell is using a reverse merger; the broader H2 IPO window is open but slow.
• No Series A announcements. Today’s small-cap news is dominated by clinical/regulatory milestones and M&A, not by new financings.
• No FDA adcomms with negative outcomes. Today’s single adcomm (BPC-157) was positive; the compounding adcomm for peptides (Fierce Pharma, 2026-07-23) also broke favorably for the industry.

Reading order (5 highest-signal items)

1. “Trump threatens tariffs on imported generic drugs” (BioPharma Dive, 2026-07-24) — the largest single market-structure story of the day.
2. “FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157” (Endpoints News, 2026-07-24) — the most novel regulatory action.
3. “Sartorius reduces revenue by €26M to refund Trump tariffs to customers” (Endpoints News, 2026-07-24) — first concrete operational disclosure of the tariff impact.
4. “FDA plans to name permanent CBER, CDER heads with new commissioner nomination” (Endpoints News, 2026-07-22) — the agency leadership transition.
5. “Scribe records upsized $129M IPO to fund genetic med trials” (Fierce Biotech, 2026-07-24) — the cleanest H2 2026 IPO signal.

How to read the underlying articles

The 63 individual news items are in ~/my-repos/openbionews.com/src/content/news/. Each file is frontmatter only (no body); the frontmatter carries title, description, pubDate, category, tags, draft, companyId (when applicable), sourceUrl, and sourceName. The sourceUrl field is the original article URL — open that in a browser to read the full body. The description field is the title itself because the cron doesn’t fetch article bodies; treat the description as a placeholder, not as a summary of the body. The companyId field is the kebab-case slug of the company JSON in src/content/companies/.

Numbered list of all 63 items

The full canonical citation list (source name + date + title):

1. Endpoints News, 2026-07-24 — Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
2. Endpoints News, 2026-07-24 — CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
3. Endpoints News, 2026-07-24 — Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67
4. Endpoints News, 2026-07-24 — Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
5. Endpoints News, 2026-07-24 — Sanofi nixes Kymab-originated OX40L antibody in eczema
6. Endpoints News, 2026-07-24 — Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing
7. Endpoints News, 2026-07-24 — FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
8. Endpoints News, 2026-07-24 — FDA to end pilot aimed at preventing production issues
9. Endpoints News, 2026-07-24 — Sartorius reduces revenue by €26M to refund Trump tariffs to customers
10. Endpoints News, 2026-07-23 — Biogen bets newly acquired Apellis can paper over Leqembi’s disappointing sales into 2027
11. Endpoints News, 2026-07-23 — Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buy
12. Endpoints News, 2026-07-23 — How the FDA is unwinding the Makary era, and making way for a new commissioner
13. Endpoints News, 2026-07-22 — Former cancer chief Pazdur says FDA has ‘golden opportunity’ to kill CDER and restructure
14. Endpoints News, 2026-07-22 — FDA approves Nuvalent’s cancer drug, a week after GSK closed $10.6B buyout
15. Endpoints News, 2026-07-22 — Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
16. Endpoints News, 2026-07-22 — Indian generic drugmaker gets FDA warning over clinical study consent
17. Endpoints News, 2026-07-22 — FDA plans to name permanent CBER, CDER heads with new commissioner nomination
18. Endpoints News, 2026-07-22 — Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
19. Endpoints News, 2026-07-22 — Trump pledges new tariffs on generic drugs not made in the US
20. PR Newswire FDA, 2026-07-24 — Asymchem’s Dunhua 2 Carbapenem Manufacturing Site Successfully Completes its First FDA Inspection for Continuous Manufacturing of an API
21. PR Newswire FDA, 2026-07-24 — Roche receives FDA clearance for the cobas BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
22. PR Newswire FDA, 2026-07-23 — VELMENI Receives FDA 510(k) Clearance for AI-Powered 3D CBCT Dental Imaging Software
23. PR Newswire FDA, 2026-07-23 — FDA Clears Momentis Surgical’s Anovo System for Multiport Surgery, Making It the First Robotic Platform to Support Three Surgical Approaches
24. PR Newswire FDA, 2026-07-23 — SimBioSys and Ferrum Health Partner to Expand Access to AI-Powered Surgical Planning Through Ferrum’s AI Governance Suite
25. PR Newswire FDA, 2026-07-23 — Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
26. PR Newswire FDA, 2026-07-23 — Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World’s First Fully Recoverable Self-Expanding Dry-Valve TAVR System
27. PR Newswire FDA, 2026-07-22 — Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
28. PR Newswire FDA, 2026-07-22 — Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
29. PR Newswire FDA, 2026-07-22 — Wisner Baum’s Lawsuits Challenge FDA Oversight of Spinal Cord Implants
30. PR Newswire FDA, 2026-07-21 — ORASIS PHARMACEUTICALS DOUBLES DOWN ON EYE CARE PROFESSIONALS, NOT TELEHEALTH, AS QLOSI REFILLS REACH 49%
31. PR Newswire FDA, 2026-07-21 — Synergy Disc Reaches 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.
32. Fierce Pharma, 2026-07-24 — Ipsen’s liver disease drug Bylvay fails biliary atresia trial
33. Fierce Pharma, 2026-07-24 — Merck prepares expanded access to monthly PrEP pill early
34. Fierce Pharma, 2026-07-24 — GSK’s first lung cancer approval, a new IPO path and more
35. Fierce Pharma, 2026-07-24 — Generic tariffs, Samsung Bio, HK IPO — Fierce Pharma Asia
36. Fierce Pharma, 2026-07-23 — J&J bispecific combo delivers 89% PFS benefit in myeloma
37. Fierce Pharma, 2026-07-23 — FDA panel favors peptides on 1st day of compounding adcomm
38. Fierce Pharma, 2026-07-23 — Roche defends 6B franc Vabysmo peak target despite another miss
39. Fierce Pharma, 2026-07-23 — BeOne joins reshoring parade with $300M US production expansion
40. Fierce Biotech, 2026-07-24 — Sanofi won’t seek approval for eczema drug from Kymab buyout
41. Fierce Biotech, 2026-07-24 — Scribe records upsized $129M IPO to fund genetic med trials
42. Fierce Biotech, 2026-07-24 — Biogen R&D vet gets in Formation — Chutes & Ladders
43. Fierce Biotech, 2026-07-23 — Scancell heads to Nasdaq via reverse merger with Neuphoria
44. Fierce Biotech, 2026-07-23 — Lilly triple-G drug hits 22% weight loss, cardio impact unclear
45. STAT News, 2026-07-24 — Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
46. STAT News, 2026-07-24 — I may be one of the last middle-class medical students who could afford to become a doctor
47. STAT News, 2026-07-24 — The U.S. pharmaceutical supply chain problem is not about China
48. STAT News, 2026-07-23 — U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
49. STAT News, 2026-07-23 — Senate health panel delays vote on CDC nominee
50. STAT News, 2026-07-23 — Filing of bipartisan Senate bill boosts momentum for office of men’s health
51. STAT News, 2026-07-21 — Trump administration says it’s deferring $1B in Medicaid payments to California and Minnesota
52. BioSpace, 2026-07-24 — Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
53. BioSpace, 2026-07-24 — Amgen deploys patients to defend troubled Tavneos in FDA hearing request
54. BioSpace, 2026-07-22 — Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
55. BioSpace, 2026-07-22 — Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
56. BioSpace, 2026-07-22 — Roche cans one Carmot obesity asset as another shows best-in-class potential
57. BioSpace, 2026-07-22 — 6 companies hiring in Cambridge now
58. BioSpace, 2026-07-21 — Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
59. BioPharma Dive, 2026-07-24 — Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
60. BioPharma Dive, 2026-07-24 — Trump threatens tariffs on imported generic drugs
61. BioPharma Dive, 2026-07-24 — Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
62. MedCity News, 2026-07-01 — CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
63. MedCity News, 2026-07-01 — Four Ways Health Systems Should Plan for the Next Wave of Breakthrough Therapies